Clinical Trial Update: Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial investigated lenalidomide, ixazomib, and rituximab as front-line therapy for high-risk indolent B-cell lymphoma; the study is terminated with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Indolent Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Rituximab (rituximab)
• ixazomib (ixazomib)

Snippet

Sponsor: Brian Hill | Conditions: B Cell Lymphoma, Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-01-13